Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus concurrent indacaterol plus glycopyrronium in moderate to severe COPD
NL-OMON37459Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing QVA149 fixed-dose combination with Concurrent indacaterol plus glycopyrronium bromide (2 arms). Primary endpoint: Trough FEV1 at week 4. Started May 2012; status: active, not recruiting.
02
Drugs
indacaterol + glycopyrroniumindacaterolglycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON37459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37459.